WindMIL Therapeutics

11 articles with WindMIL Therapeutics

• 

  Clinical Catch-Up: May 25-29

  6/1/2020

  In the lead-up to the ASCO Annual Meeting, companies were presenting some of their trial data, while other companies were presenting news related to COVID-19 studies. Here’s a look.
• 

  Clinical Catch-Up: April 20-24

  4/27/2020

  Despite the domination of the news cycle by the COVID-19 pandemic, quite a number of biopharma companies reported on non-COVID-19 clinical trials last week, although there remains plenty of ongoing trial news related to the pandemic. Here’s a look.

• WindMIL Therapeutics and Cognate BioServices Announce Agreement to Expand MILs Manufacturing Capacity

  3/10/2020

  WindMIL Therapeutics and Cognate BioServices, Inc. announced they have entered an agreement to expand WindMIL’s clinical manufacturing capacity.

• WindMIL Therapeutics and Providence Cancer Institute Announce Collaboration to Collect Bone Marrow from Patients with Breast Cancer to Develop Marrow-Infiltrating Lymphocytes (MILs™)

  2/11/2020

  WindMIL Therapeutics and Providence Cancer Institute announced that the first patient has been identified in an investigator-sponsored study for the collection of bone marrow from patients with breast cancer.

• WindMIL Therapeutics Announces Cancer Immunotherapy Pre-Clinical Research Collaboration with University of Pennsylvania

  2/5/2020

  WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocytes (MILs™) for cancer immunotherapy, today announced a collaborative pre-clinical research partnership with University of Pennsylvania (Penn) to explore novel chimeric antigen receptor (CAR)-engineered MILs (CAR-MILs™) in hematological and solid tumor model settings.

• WindMIL Therapeutics Announces Clinical Research Collaboration with Bristol-Myers Squibb to Evaluate Marrow-Infiltrating Lymphocytes (MILs™) in Combination with nivolumab (Opdivo®) for Treatment of Patients with Non-Small Cell Lung Cancer

  12/23/2019

  This open-label, multi-center Phase 2a clinical trial will assess the safety and efficacy of MILs alone and in combination with nivolumab.

• 

  Clinical Catch-Up: December 9-13

  12/16/2019

  It was a particularly busy week in clinical trial news, largely because of the American Society of Hematology Annual Meeting. Here’s a look.

• WindMIL Therapeutics and University of Michigan Announce Collaboration to Collect Bone Marrow from Patients with Head and Neck Cancer to Develop Marrow Infiltrating Lymphocytes (MILs™)

  7/9/2019

  WindMIL Therapeutics and the University of Michigan Rogel Cancer Center today announced that the first patients have been identified in an investigator-sponsored study for the collection of bone marrow from patients with head and neck squamous cell carcinoma.

• WindMIL Therapeutics Announces $32.5 Million in Series B Financing

  6/18/2018

  Phase 2, multi-center randomized trial of MILs™ in high-risk multiple myeloma fully enrolled

• 

  WindMIL Therapeutics Raises $32.53 Million

  6/18/2018

  WindMIL Therapeutics, based in Baltimore, Maryland, filed a form D with the U.S. Securities and Exchange Commission, indicating it had raised $32.53 million in equity financing.

• WindMIL Therapeutics Announces New Cancer Immunotherapy Approach Based On Marrow-Infiltrating Lymphocytes

  10/5/2017